Royal Biologics acquisition strengthens spinal fusion portfolio

Alan Condon -   Print  |

Orthobiologics company Royal Biologics acquired the Fibrinet system from Vertical Spine Sept. 1.

Five things to know:

1. The acquisition bolsters Royal Biologics' portfolio of autologous and live cellular solutions for orthopedic and spinal fusion. 

2. Fibrinet uses a patient's own autologous blood to create a platelet-rich fibrin matrix/membrane, which can help facilitate spinal fusion.

3. The solution creates a biologic supply of growth factors and stem cells that can be held and used at the point of care for spinal fusion.

4. Many hospitals have incorporated Fibrinet into their spine offerings, including Hospital for Special Surgery, Mount Sinai, and NewYork-Presbyterian, all in New York City.

5. Terms of the transaction were not disclosed.

More articles on biologics:
Meet Elon Musk's surgical robot
Laser Spine Institute 18 months after closure — What happened to its $56M Tampa HQ?
Vertebral body tethering shows success in the treatment of scoliosis, study finds

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers